We also used CRISPR/Cas9 gene editing to silence the SLC2A5 gene in HeLa cervical cancer cells (Supplementary Figure S4A) and in breast cancer MDA-MB-231 cells (Supplementary Figure S4B). This evidence concerns the gene SLC2A5 and breast cancer.